University Hospital of RWTH Aachen - Institute of Clinical Pharmacology
The clinical pharmacological research in the institute focuses on Personalized Medicine and Pharmacogenomics and Regulatory Science. Pharmacogenetic research pioneered the systematic development of personalized dose adjustments that are now applied in clinical practice based on international guidelines. Our current research focuses are on pharmacogenetic and other patient risk profiles in drug safety, personalized medicine in the elderly, and genetic risk signatures in complex therapies. The institute is involved in many international interdisciplinary research projects with technical, computational and epidemiological expertise focusing on the development of multimodal biomarker signatures for personalized therapy such as coordination of a new Eranet project on personalized medicine ARTIPRO (funded from 2022-2025) and partner in the EU Horizon project SafePolyMed (2022-2026).
Role within SafePolyMed
In SafePolyMed, UKA leads WP2 “Patient-Reported Outcome (PROM)” together with Leukanet. The aim is to develop and validate PROMs for patient safety in collaboration with patient organisations and other stakeholders using a multi-stakeholder consensus-based Delphi process.
The validated PROMs will be implemented in the Medication Management Center (WP3) and will be validated in clinical case studies (WP5). With the implementation of a patient-centred training concept and curriculum via the patient academy EUPATI, patients and caregivers will be trained and empowered in understanding personalised treatment principles addressing the awareness and self-reporting of ADRs as well as medication errors giving attention to both PROMs for adverse event reporting and PREMs (Patient-Reported Experience Measures).